Accéder au contenu
Merck

The transcriptional repressor BCL11A promotes breast cancer metastasis.

The Journal of biological chemistry (2020-06-25)
Darcie D Seachrist, Molly M Hannigan, Natasha N Ingles, Bryan M Webb, Kristen L Weber-Bonk, Peng Yu, Gurkan Bebek, Salendra Singh, Steven T Sizemore, Vinay Varadan, Donny D Licatalosi, Ruth A Keri, Darcie D Seachrist, Molly M Hannigan, Natasha N Ingles, Bryan M Webb, Kristen L Weber-Bonk, Peng Yu, Gurkan Bebek, Salendra Singh, Steven T Sizemore, Vinay Varadan, Donny D Licatalosi, Ruth A Keri
RÉSUMÉ

The phenotypes of each breast cancer subtype are defined by their transcriptomes. However, the transcription factors that regulate differential patterns of gene expression that contribute to specific disease outcomes are not well understood. Here, using gene silencing and overexpression approaches, RNA-Seq, and splicing analysis, we report that the transcription factor B-cell leukemia/lymphoma 11A (BCL11A) is highly expressed in triple-negative breast cancer (TNBC) and drives metastatic disease. Moreover, BCL11A promotes cancer cell invasion by suppressing the expression of muscleblind-like splicing regulator 1 (MBNL1), a splicing regulator that suppresses metastasis. This ultimately increases the levels of an alternatively spliced isoform of integrin-α6 (ITGA6), which is associated with worse patient outcomes. These results suggest that BCL11A sustains TNBC cell invasion and metastatic growth by repressing MBNL1-directed splicing of ITGA6 Our findings also indicate that BCL11A lies at the interface of transcription and splicing and promotes aggressive TNBC phenotypes.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-Integrin α6B Antibody, cytoplasmic domain, clone 6B4, clone 6B4, Chemicon®, from mouse